Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 403

1.

Copolymerization of single cell nucleic acids into balls of acrylamide gel.

Li S, Kendall J, Park S, Wang Z, Alexander J, Moffitt A, Ranade N, Danyko C, Gegenhuber B, Fischer S, Robinson BD, Lepor H, Tollkuhn J, Gillis J, Brouzes E, Krasnitz A, Levy D, Wigler M.

Genome Res. 2019 Nov 14. pii: gr.253047.119. doi: 10.1101/gr.253047.119. [Epub ahead of print]

PMID:
31727682
2.

EDITORIAL COMMENT.

Lepor H.

Urology. 2019 Nov;133:179. doi: 10.1016/j.urology.2019.06.044. No abstract available.

PMID:
31706419
3.

Electronic-cigarette smoke induces lung adenocarcinoma and bladder urothelial hyperplasia in mice.

Tang MS, Wu XR, Lee HW, Xia Y, Deng FM, Moreira AL, Chen LC, Huang WC, Lepor H.

Proc Natl Acad Sci U S A. 2019 Oct 22;116(43):21727-21731. doi: 10.1073/pnas.1911321116. Epub 2019 Oct 7. Erratum in: Proc Natl Acad Sci U S A. 2019 Nov 5;116(45):22884.

4.

Gleason pattern 5 is associated with an increased risk for metastasis following androgen deprivation therapy and radiation: An analysis of RTOG 9202 and 9902.

Hamstra DA, Pugh SL, Lepor H, Rosenthal SA, Pienta KJ, Gomella L, Peters C, D'Souza DP, Zeitzer KL, Jones CU, Hall WA, Horwitz E, Pisansky TM, Souhami L, Hartford AC, Dominello M, Feng F, Sandler HM.

Radiother Oncol. 2019 Sep 17. pii: S0167-8140(19)33066-X. doi: 10.1016/j.radonc.2019.08.020. [Epub ahead of print]

PMID:
31540746
5.

Two-year Outcomes Following Focal Laser Ablation of Localized Prostate Cancer.

Chao B, Llukani E, Lepor H.

Eur Urol Oncol. 2018 Jun;1(2):129-133. doi: 10.1016/j.euo.2018.03.011. Epub 2018 May 15.

PMID:
31100236
6.

Focal Ablation of Prostate Cancer.

Lepor H, Gold S, Wysock J.

Rev Urol. 2018;20(4):145-157. doi: 10.3909/riu0809.

7.

Time Interval to Biochemical Failure as a Surrogate End Point in Locally Advanced Prostate Cancer: Analysis of Randomized Trial NRG/RTOG 9202.

Dignam JJ, Hamstra DA, Lepor H, Grignon D, Brereton H, Currey A, Rosenthal S, Zeitzer KL, Venkatesan VM, Horwitz EM, Pisansky TM, Sandler HM.

J Clin Oncol. 2019 Jan 20;37(3):213-221. doi: 10.1200/JCO.18.00154. Epub 2018 Dec 7.

PMID:
30526194
8.

Optimizing patient selection for focal therapy-mapping and ablating the index lesion.

Wysock JS, Lepor H.

Transl Androl Urol. 2018 Sep;7(Suppl 4):S519-S525. doi: 10.21037/tau.2018.03.16. No abstract available.

9.

Uroplakins play conserved roles in egg fertilization and acquired additional urothelial functions during mammalian divergence.

Liao Y, Chang HC, Liang FX, Chung PJ, Wei Y, Nguyen TP, Zhou G, Talebian S, Krey LC, Deng FM, Wong TW, Chicote JU, Grifo JA, Keefe DL, Shapiro E, Lepor H, Wu XR, DeSalle R, Garcia-España A, Kim SY, Sun TT.

Mol Biol Cell. 2018 Oct 10:mbcE18080496. doi: 10.1091/mbc.E18-08-0496. [Epub ahead of print]

10.

Focal Ablation of Prostate Cancer.

Lepor H.

Rev Urol. 2018;20(2):107-111. doi: 10.3909/riu0812. No abstract available.

11.

Management Options for Nocturia.

Lepor H, Dmochowski RR.

Rev Urol. 2018;20(2):53-55. doi: 10.3909/riu0811. No abstract available.

12.

Prostate Cancers Detected by Magnetic Resonance Imaging-Targeted Biopsies Have a Higher Percentage of Gleason Pattern 4 Component and Are Less Likely to Be Upgraded in Radical Prostatectomies.

Zhao Y, Deng FM, Huang H, Lee P, Lepor H, Rosenkrantz AB, Taneja S, Melamed J, Zhou M.

Arch Pathol Lab Med. 2019 Jan;143(1):86-91. doi: 10.5858/arpa.2017-0410-OA. Epub 2018 Jul 2.

PMID:
29965785
13.

Long-term Natural History of Lower Urinary Tract Symptoms Following Radical Retropubic Prostatectomy: A Prospective 15-Year Longitudinal Study.

Xu AJ, Taksler GB, Llukani E, Lepor H.

Urology. 2018 Oct;120:167-172. doi: 10.1016/j.urology.2018.06.014. Epub 2018 Jun 25.

PMID:
29953883
14.

Aldehydes are the predominant forces inducing DNA damage and inhibiting DNA repair in tobacco smoke carcinogenesis.

Weng MW, Lee HW, Park SH, Hu Y, Wang HT, Chen LC, Rom WN, Huang WC, Lepor H, Wu XR, Yang CS, Tang MS.

Proc Natl Acad Sci U S A. 2018 Jul 3;115(27):E6152-E6161. doi: 10.1073/pnas.1804869115. Epub 2018 Jun 18.

15.

The Institutional Learning Curve of Magnetic Resonance Imaging-Ultrasound Fusion Targeted Prostate Biopsy: Temporal Improvements in Cancer Detection in 4 Years.

Meng X, Rosenkrantz AB, Huang R, Deng FM, Wysock JS, Bjurlin MA, Huang WC, Lepor H, Taneja SS.

J Urol. 2018 Nov;200(5):1022-1029. doi: 10.1016/j.juro.2018.06.012. Epub 2018 Jun 7.

PMID:
29886090
16.

Use of Conservative Management for Low-Risk Prostate Cancer in the Veterans Affairs Integrated Health Care System From 2005-2015.

Loeb S, Byrne N, Makarov DV, Lepor H, Walter D.

JAMA. 2018 Jun 5;319(21):2231-2233. doi: 10.1001/jama.2018.5616. No abstract available.

17.

Long-Term Continence Outcomes in Men Undergoing Radical Prostatectomy: A Prospective 15-Year Longitudinal Study.

Xu AJ, Taksler GB, Llukani E, Lepor H.

J Urol. 2018 Sep;200(3):626-632. doi: 10.1016/j.juro.2018.05.005. Epub 2018 May 7.

PMID:
29746859
18.

Health state utilities among contemporary prostate cancer patients on active surveillance.

Loeb S, Curnyn C, Walter D, Fagerlin A, Siebert U, Mühlberger N, Braithwaite RS, Schwartz MD, Lepor H, Sedlander E.

Transl Androl Urol. 2018 Apr;7(2):197-202. doi: 10.21037/tau.2017.03.80.

19.

E-cigarette smoke damages DNA and reduces repair activity in mouse lung, heart, and bladder as well as in human lung and bladder cells.

Lee HW, Park SH, Weng MW, Wang HT, Huang WC, Lepor H, Wu XR, Chen LC, Tang MS.

Proc Natl Acad Sci U S A. 2018 Feb 13;115(7):E1560-E1569. doi: 10.1073/pnas.1718185115. Epub 2018 Jan 29.

20.

Utility of Single-Cell Genomics in Diagnostic Evaluation of Prostate Cancer.

Alexander J, Kendall J, McIndoo J, Rodgers L, Aboukhalil R, Levy D, Stepansky A, Sun G, Chobardjiev L, Riggs M, Cox H, Hakker I, Nowak DG, Laze J, Llukani E, Srivastava A, Gruschow S, Yadav SS, Robinson B, Atwal G, Trotman LC, Lepor H, Hicks J, Wigler M, Krasnitz A.

Cancer Res. 2018 Jan 15;78(2):348-358. doi: 10.1158/0008-5472.CAN-17-1138. Epub 2017 Nov 27.

21.

Prediction of Prostate Cancer Risk Among Men Undergoing Combined MRI-targeted and Systematic Biopsy Using Novel Pre-biopsy Nomograms That Incorporate MRI Findings.

Bjurlin MA, Rosenkrantz AB, Sarkar S, Lepor H, Huang WC, Huang R, Venkataraman R, Taneja SS.

Urology. 2018 Feb;112:112-120. doi: 10.1016/j.urology.2017.09.035. Epub 2017 Nov 16.

PMID:
29155186
22.

The Use of Magnetic Resonance Imaging to Predict Oncological Control Among Candidates for Focal Ablation of Prostate Cancer.

Kenigsberg AP, Llukani E, Deng FM, Melamed J, Zhou M, Lepor H.

Urology. 2018 Feb;112:121-125. doi: 10.1016/j.urology.2017.10.014. Epub 2017 Oct 20.

PMID:
29061480
23.

Informational needs during active surveillance for prostate cancer: A qualitative study.

Loeb S, Curnyn C, Fagerlin A, Braithwaite RS, Schwartz MD, Lepor H, Carter HB, Ciprut S, Sedlander E.

Patient Educ Couns. 2018 Feb;101(2):241-247. doi: 10.1016/j.pec.2017.08.022. Epub 2017 Sep 1.

24.

Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions.

Loeb S, Zhou Q, Siebert U, Rochau U, Jahn B, Mühlberger N, Carter HB, Lepor H, Braithwaite RS.

Eur Urol. 2017 Dec;72(6):899-907. doi: 10.1016/j.eururo.2017.07.018. Epub 2017 Aug 23.

25.

Multiparametric magnetic resonance imaging identifies significant apical prostate cancers.

Kenigsberg AP, Tamada T, Rosenkrantz AB, Llukani E, Deng FM, Melamed J, Zhou M, Lepor H.

BJU Int. 2018 Feb;121(2):239-243. doi: 10.1111/bju.13987. Epub 2017 Sep 5.

26.

Multi-parametric MRI imaging of the prostate-implications for focal therapy.

Wysock JS, Lepor H.

Transl Androl Urol. 2017 Jun;6(3):453-463. doi: 10.21037/tau.2017.04.29. Review.

27.

Magnetic resonance imaging in prostate cancer.

Bjurlin MA, Rosenkrantz AB, Lepor H, Taneja SS.

Transl Androl Urol. 2017 Jun;6(3):343-344. doi: 10.21037/tau.2017.05.16. No abstract available.

28.

Editorial Comment.

Lepor H.

J Urol. 2017 Aug;198(2):343-344. doi: 10.1016/j.juro.2017.03.143. Epub 2017 May 15. No abstract available.

PMID:
28521143
29.

Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202.

Lawton CAF, Lin X, Hanks GE, Lepor H, Grignon DJ, Brereton HD, Bedi M, Rosenthal SA, Zeitzer KL, Venkatesan VM, Horwitz EM, Pisansky TM, Kim H, Parliament MB, Rabinovitch R, Roach M 3rd, Kwok Y, Dignam JJ, Sandler HM.

Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):296-303. doi: 10.1016/j.ijrobp.2017.02.004. Epub 2017 Feb 12.

30.

Benign Prostatic Obstruction Relief in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Enlargement Undergoing Endoscopic Surgical Procedures or Therapy with Alpha-Blockers: A Review of Urodynamic Studies.

Fusco F, Creta M, Imperatore V, Longo N, Imbimbo C, Lepor H, Mirone V.

Adv Ther. 2017 Apr;34(4):773-783. doi: 10.1007/s12325-017-0504-0. Epub 2017 Mar 2. Review.

PMID:
28255867
31.

Aetiology and management of earlier vs later biochemical recurrence after retropubic radical prostatectomy.

Llukani E, Lepor H.

BJU Int. 2017 Oct;120(4):505-510. doi: 10.1111/bju.13816. Epub 2017 Mar 14.

32.

Prostate Cancer Academy 2016: Presentation summaries.

Crawford ED, Albala DM, Wysocki JS, Lepor H, Ross AE, Finkelstein SE, Keane T, Freedland S, Harris R, Shore ND, Ryan CJ.

Rev Urol. 2016;18(4):205-213. doi: 10.3909/riuPCA2016. No abstract available.

33.

Effect of Long-Term Hormonal Therapy (vs Short-Term Hormonal Therapy): A Secondary Analysis of Intermediate-Risk Prostate Cancer Patients Treated on NRG Oncology RTOG 9202.

Mirhadi AJ, Zhang Q, Hanks GE, Lepor H, Grignon DJ, Peters CA, Rosenthal SA, Zeitzer K, Radwan JS, Lawton C, Parliament MB, Reznik RS, Sandler HM.

Int J Radiat Oncol Biol Phys. 2017 Mar 1;97(3):511-515. doi: 10.1016/j.ijrobp.2016.11.002. Epub 2016 Nov 8.

34.

Surgical Treatment of Prostate Carcinoma.

Lepor H.

J Urol. 2017 Feb;197(2S):S41-S42. doi: 10.1016/j.juro.2016.10.084. Epub 2016 Dec 20. No abstract available.

PMID:
28010978
35.
36.

Risk Stratification by Urinary Prostate Cancer Gene 3 Testing Before Magnetic Resonance Imaging-Ultrasound Fusion-targeted Prostate Biopsy Among Men With No History of Biopsy.

Fenstermaker M, Mendhiratta N, Bjurlin MA, Meng X, Rosenkrantz AB, Huang R, Deng FM, Zhou M, Huang WC, Lepor H, Taneja SS.

Urology. 2017 Jan;99:174-179. doi: 10.1016/j.urology.2016.08.022. Epub 2016 Aug 22.

PMID:
27562202
37.

Risk of Small Bowel Obstruction After Robot-Assisted vs Open Radical Prostatectomy.

Loeb S, Meyer CP, Krasnova A, Curnyn C, Reznor G, Kibel AS, Lepor H, Trinh QD.

J Endourol. 2016 Dec;30(12):1291-1295.

PMID:
27615204
38.

Qualitative study on decision-making by prostate cancer physicians during active surveillance.

Loeb S, Curnyn C, Fagerlin A, Braithwaite RS, Schwartz MD, Lepor H, Carter HB, Sedlander E.

BJU Int. 2017 Jul;120(1):32-39. doi: 10.1111/bju.13651. Epub 2016 Oct 2.

39.

New and Established Technology in Focal Ablation of the Prostate: A Systematic Review.

Valerio M, Cerantola Y, Eggener SE, Lepor H, Polascik TJ, Villers A, Emberton M.

Eur Urol. 2017 Jan;71(1):17-34. doi: 10.1016/j.eururo.2016.08.044. Epub 2016 Aug 29. Review.

PMID:
27595377
40.

Detection of prostate cancer local recurrence following radical prostatectomy: assessment using a continuously acquired radial golden-angle compressed sensing acquisition.

Rosenkrantz AB, Khasgiwala A, Doshi AM, Ream JM, Taneja SS, Lepor H.

Abdom Radiol (NY). 2017 Jan;42(1):290-297. doi: 10.1007/s00261-016-0881-x.

41.

Alpha-blockers for the Treatment of Benign Prostatic Hyperplasia.

Lepor H.

Urol Clin North Am. 2016 Aug;43(3):311-23. doi: 10.1016/j.ucl.2016.04.009. Review.

PMID:
27476124
42.

Editorial Comment.

Lepor H.

Urology. 2016 Jul;93:74. doi: 10.1016/j.urology.2016.02.058. Epub 2016 May 11. No abstract available.

PMID:
27179945
43.

Practical Barriers to Obtaining Pre-Biopsy Prostate MRI: Assessment in Over 1,500 Consecutive Men Undergoing Prostate Biopsy in a Single Urologic Practice.

Rosenkrantz AB, Lepor H, Huang WC, Taneja SS.

Urol Int. 2016;97(2):247-8. doi: 10.1159/000446003. Epub 2016 Apr 29. No abstract available.

PMID:
27160263
44.

Testosterone Deficiency and the Prostate.

Alukal JP, Lepor H.

Urol Clin North Am. 2016 May;43(2):203-8. doi: 10.1016/j.ucl.2016.01.013. Review.

PMID:
27132577
45.

Editorial Comment.

Lepor H.

Urology. 2016 May;91:116-7. doi: 10.1016/j.urology.2015.12.076. No abstract available.

PMID:
27107188
46.

Teaching Hospitals and the Disconnect Between Technology Adoption and Comparative Effectiveness Research: The Case of the Surgical Robot.

Makarov DV, Li H, Lepor H, Gross CP, Blustein J.

Med Care Res Rev. 2017 Jun;74(3):369-376. doi: 10.1177/1077558716642690. Epub 2016 Mar 30.

PMID:
27034439
47.

How Active is Active Surveillance? Intensity of Followup during Active Surveillance for Prostate Cancer in the United States.

Loeb S, Walter D, Curnyn C, Gold HT, Lepor H, Makarov DV.

J Urol. 2016 Sep;196(3):721-6. doi: 10.1016/j.juro.2016.02.2963. Epub 2016 Mar 2.

48.

The Challenge for Urologists Is to Screen, Detect, and Treat Prostate Cancer "Smarter": Will Ablative Technology Result in Smarter Treatment?

Lepor H.

Eur Urol. 2016 Sep;70(3):456-7. doi: 10.1016/j.eururo.2016.01.024. Epub 2016 Jan 20. No abstract available.

PMID:
26803477
49.

Predictive value of negative 3T multiparametric magnetic resonance imaging of the prostate on 12-core biopsy results.

Wysock JS, Mendhiratta N, Zattoni F, Meng X, Bjurlin M, Huang WC, Lepor H, Rosenkrantz AB, Taneja SS.

BJU Int. 2016 Oct;118(4):515-20. doi: 10.1111/bju.13427. Epub 2016 Feb 25.

50.

The Role of Minimally Invasive Surgical Techniques in the Management of Large-gland Benign Prostatic Hypertrophy.

Sivarajan G, Borofsky MS, Shah O, Lingeman JE, Lepor H.

Rev Urol. 2015;17(3):140-9.

Supplemental Content

Support Center